WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016083818) N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/083818    International Application No.:    PCT/GB2015/053613
Publication Date: 02.06.2016 International Filing Date: 26.11.2015
IPC:
C07D 401/14 (2006.01), C07D 413/14 (2006.01), A61K 31/415 (2006.01), A61K 31/454 (2006.01), A61K 31/4709 (2006.01), A61K 31/497 (2006.01), A61K 31/506 (2006.01), C07D 231/14 (2006.01), C07D 401/06 (2006.01), C07D 401/10 (2006.01), C07D 403/10 (2006.01), C07D 409/14 (2006.01), C07D 405/14 (2006.01), A61K 31/416 (2006.01), A61K 31/4439 (2006.01)
Applicants: KALVISTA PHARMACEUTICALS LIMITED [GB/GB]; Building 227 Tetricus Science Park Porton Down Salisbury SP4 0JQ (GB)
Inventors: EVANS, David Michael; (GB).
DAVIE, Rebecca Louise; (GB).
EDWARDS, Hannah Joy; (GB).
HODGSON, Simon Teanby; (GB)
Agent: PHILLIPS, Gillian Margaret; (GB)
Priority Data:
1421085.0 27.11.2014 GB
Title (EN) N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS
(FR) COMPOSÉS N-((HET)ARYLMÉTHYL)-HÉTÉROARYL-CARBOXAMIDES EN TANT QU'INHIBITEURS DE KALLIKRÉINE
Abstract: front page image
(EN)The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.
(FR)La présente invention concerne des composés de formule (I), des compositions comportant de tels composés, l'utilisation de tels composés en thérapie (par exemple dans le traitement ou la prévention d'une maladie ou d'un état pathologique dans lesquels l'activité de la kallicréine plasmatique est impliquée), et des procédés de traitement de patients avec de tels composés; dans la formule (I) R5, R6, R7, A, B, U, D, E, W, X, Y et Z sont tels que définis dans la description.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)